Lv2
135 积分 2024-03-15 加入
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已关闭
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1个月前
已关闭
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
1个月前
已完结
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
1个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
4个月前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
DESTINY-Breast09: Trastuzumab Deruxtecan Plus Pertuzumab Sets New First-Line Benchmark in HER2-Positive Metastatic Breast Cancer
5个月前
已关闭
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
5个月前
已完结
皖公网安备34019202002308
